# CBD Pet Market Hits $577 Million as Maryland Joins States Protecting Vet Cannabis Conversations
**The global pet CBD market surged past half a billion dollars in 2026 while state legislatures are clearing the way for veterinarians to talk openly about cannabis treatments.**
*By CBDWorldNews Editorial Staff | April 15, 2026*
Market Growth Accelerates
The global CBD pet market reached an estimated $577 million in 2026, according to research firm Future Market Insights. The firm projects the category will hit $5.5 billion by 2034, growing at a compound annual rate of 32.5% as veterinary acceptance, product quality, and consumer awareness develop together.
Those projections reflect a market that has matured past its novelty phase. Pet parents are no longer early adopters experimenting with an unfamiliar supplement. They’re repeat buyers who have watched their animals respond to CBD products and integrated them into regular care routines.
The growth tracks with broader trends in pet spending. Americans spent a record $186 billion on their pets in 2025, with health and wellness products growing faster than any other category. CBD sits at the intersection of two powerful consumer trends: humanization of pets and preference for natural health approaches.
Maryland Opens the Vet’s Office Door
In March, Maryland delegates unanimously passed a bill that protects veterinarians from licensing board discipline when they discuss cannabis treatment options with their animal patients’ families. The bill removes a chilling effect that has kept many vets silent about CBD even as their clients ask about it.
The problem has been straightforward. Veterinarians who recommend or discuss cannabis-derived products have risked complaints to state licensing boards. Even in states where hemp-derived CBD is legal for retail sale, professional guidance from vets has existed in a gray zone. Some veterinarians reported receiving board inquiries after mentioning CBD to clients, creating a perverse situation where pet parents could buy CBD products freely but couldn’t get professional advice on using them safely.
“Pet parents have been dosing their animals based on internet forums and product labels. Giving veterinarians the legal cover to actually guide these conversations is a patient safety issue.” — Veterinary policy advocate, March 2026
Maryland joins California, Colorado, and Oregon, which passed similar protections in prior legislative sessions. The trend suggests a growing recognition that veterinary silence on CBD doesn’t reduce usage — it just makes it less informed.
Research Backs the Conversation
Recent veterinary research gives vets more to discuss. A Cornell University College of Veterinary Medicine study found that CBD oil at 2 mg/kg twice daily significantly decreased pain and increased activity in dogs with osteoarthritis. More than 80% of dogs in the study showed measurable improvement in pain scores and mobility with no observable side effects.
A larger observational study analyzing data from over 47,000 dogs found that long-term CBD use was linked to reduced aggression over time. The study, published in late 2025, represents one of the largest datasets ever assembled on pet CBD use and provides the kind of population-level evidence that veterinary professionals need to make informed recommendations.
However, the research landscape is not uniformly positive. A study of 183 dogs receiving CBD products from more than 40 brands found wildly inconsistent blood concentrations — ranging from non-detectable to over 1,000 ng/mL, with a median of just 13.7 ng/mL. Some products contained no detectable CBD at all.
That finding underscores why veterinary guidance matters. Without professional input, pet parents have no way to distinguish effective products from expensive placebos. [CBDPet.com’s dosing guide](https://cbdpet.com/dosing-guide) offers starting points, but a veterinary relationship remains the safest path to appropriate use.
The Quality Gap Persists
Product quality remains the pet CBD market’s biggest vulnerability. Unlike human pharmaceuticals and even human dietary supplements, pet CBD products face minimal federal oversight. The FDA has not established manufacturing standards specific to animal CBD products, and enforcement actions have focused on companies making explicit health claims rather than on product quality itself.
Third-party testing offers the best available safeguard. Brands that publish Certificates of Analysis from independent labs allow pet parents and veterinarians to verify CBD content, THC levels, and the absence of contaminants like pesticides and heavy metals. [SafeCBD.com maintains a directory of testing standards](https://safecbd.com/pet-testing) specific to animal products.
The companies best positioned for long-term growth are those investing in veterinary-grade manufacturing standards now, before regulation forces the issue. [CBDProducts.com tracks which brands meet clinical testing standards](https://cbdproducts.com/pet-cbd-reviews) across both human and animal product lines.
What’s Ahead
The pet CBD market faces the same November 2026 regulatory cliff as the broader hemp industry. If the federal THC threshold drops to 0.4 milligrams per container, many pet CBD products — particularly full-spectrum formulations — could lose their legal status.
For now, the market’s trajectory points sharply upward. More states protecting vet conversations, growing research support, and rising consumer spending on pet wellness create favorable conditions. The question is whether regulatory headwinds will slow the momentum before the market reaches its projected potential.
